Last reviewed · How we verify

mRNA-1273 vaccine — Competitive Intelligence Brief

mRNA-1273 vaccine (mRNA-1273 vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mRNA vaccine. Area: Immunology / Infectious Disease.

marketed mRNA vaccine SARS-CoV-2 spike protein Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

mRNA-1273 vaccine (mRNA-1273 vaccine) — University Health Network, Toronto. mRNA-1273 is an mRNA vaccine that instructs cells to produce the SARS-CoV-2 spike protein, triggering an immune response to prevent COVID-19 infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
mRNA-1273 vaccine TARGET mRNA-1273 vaccine University Health Network, Toronto marketed mRNA vaccine SARS-CoV-2 spike protein
BNT162b7 Monovalent (OMI BA.4/BA.5) bnt162b7-monovalent-omi-ba-4-ba-5 Pfizer marketed vaccine SARS-CoV-2 spike protein
Famtozinameran 5 to 11 Years of age famtozinameran-5-to-11-years-of-age Pfizer marketed Monoclonal antibody SARS-CoV-2 spike protein
Comirnaty Original/Omicron BA.4-5 Comirnaty Original/Omicron BA.4-5 Jules Bordet Institute marketed mRNA vaccine SARS-CoV-2 spike protein (original strain and Omicron BA.4-5 variants)
Novavax recombinant protein vaccine Novavax recombinant protein vaccine Henry M. Jackson Foundation for the Advancement of Military Medicine marketed Recombinant protein vaccine Viral surface antigens (e.g., SARS-CoV-2 spike protein)
Moderna mRNA-1273 COVID-19 vaccine Moderna mRNA-1273 COVID-19 vaccine National Institute of Allergy and Infectious Diseases (NIAID) marketed mRNA vaccine SARS-CoV-2 spike protein (S protein)
BNT162b2 Bivalent (WT/OMI BA.1) bnt162b2-bivalent-wt-omi-ba-1 Pfizer marketed mRNA vaccine SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mRNA vaccine class)

  1. Pfizer · 12 drugs in this class
  2. ModernaTX, Inc. · 11 drugs in this class
  3. BioNTech SE · 5 drugs in this class
  4. Jules Bordet Institute · 5 drugs in this class
  5. Tan Tock Seng Hospital · 2 drugs in this class
  6. Clover Biopharmaceuticals AUS Pty · 1 drug in this class
  7. CanSino Biologics Inc. · 1 drug in this class
  8. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
  9. CSPC Megalith Biopharmaceutical Co.,Ltd. · 1 drug in this class
  10. Jens D Lundgren, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). mRNA-1273 vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/mrna-1273-vaccine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: